Combination Therapies Comprising Daratumumab, Bortezomib, Thalidomide and Dexamethasone and Their Uses

A method of treating multiple myeloma in a newly diagnosed subject who is eligible for autologous stem cell transplant (ASCT), comprising:

• a) administering to the subject, during an induction phase comprising four consecutive 4-week treatment cycles (Cycles 1-4):
• i) daratumumab once a week for Cycles 1 and 2, once every two weeks for Cycles 3 and 4;
• ii) bortezomib twice a week on Week 1 and Week 2;
• iii) thalidomide daily;
• and
• iv) dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 of Cycles 1 and 2 and on Days 1, 2, 8, 9, 15, and 16 of Cycles 3 and 4;
• and
• b) administering to the subject, during a consolidation phase comprising two consecutive 4-week treatment cycles (Cycles 5 and 6) following ASCT:
• i) daratumumab every two weeks;
• ii) bortezomib twice a week on Week 1 and Week 2;
• iii) thalidomide daily;
• and
• iv) dexamethasone on Days 1, 2, 8, 9, 15, and 16;
• wherein the subject achieves a stringent complete response, a complete response, a very good partial response, or a partial response on Day 100 following the ASCT.